Glioblastoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Concurrent Bevacizumab and RT, then Irinotecan and Bevacizumab maintenance Variant #01 | — | R 96 316 | 56d | — | — | ~2 | ~R 116 303 indirect | — |
Temozolomide and RT Variant #01 | — | R 19 131 | 45d | ~7.9 mo | ~18.7 mo | ~12 | ~R 59 601 PFS proxy · indirect | 7 |
PCV Variant #02 Partial | — | R 327 | 56d | — | ~57.6 mo | ~6 | ~R 1 959 PFS proxy · indirect | 3 |
Carmustine and RT Variant #01 Partial | — | — | 42d | — | ~10.6 mo | ~7 | — | 1 |
Nimustine and RT Variant #01 Partial | — | — | — | — | ~27.4 mo | ~1 | — | — |
Radiation therapy N/A - radiation | — | — | 49d | — | ~7.5 mo | — | — | 7 |
6 of 6 regimens shown